Ron has over 20 years experience in the pharmaceutical industry and directed the Cardiovascular Therapeutics Discovery Effort at Pharmacia & Upjohn from 1990-1998. In 1998, Ron started a pharmaceutical cardiovascular research-consulting firm (CVR2000, LLC) and joined the Apjohn Group in 2003. Most recently, Ron has served as the CSO for MedElute, Inc. since 2005. Previous to directing the cardiovascular group at Pharmacia & Upjohn, Ron was a Senior Scientist responsible for leading cardiovascular drug discovery teams at Merck Research Laboratories and Smith Kline & French in the Philadelphia area. He received his B.S. Degree in Microbiology from the University of Wisconsin at Madison and Ph.D. Degree in Pharmacology from the University of Minnesota Medical School. Ron's primary field of research and development has focused on platelet and coagulation activation in thrombosis and the development of effective new biomedical devices to prevent post-surgical adhesions -- a major cause of complications and death following thoracic and abdominal surgeries.

Selected Papers:

• Morris, J. and Shebuski, R.J. Small molecule approaches to prevention of restenosis. Current Pharmaceutical Design. 1: 469-482, 1995.

• Song, C.X., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W.R., Shebuski, R.J., and Levy, R.J. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. Journal of Controlled Release. 43:197-212, 1997.

• Humphrey, W.R., Erickson, L.A., Simmons, C.A., Northrup, J.L., Wishka, D.G., Morris, J., Labhasetwar, V., Song, C., Levy, R.J., and Shebuski, R.J. The effect of intramural delivery of polymeric nanoparticles loaded with the antiproliferative 2-aminochromone U-86983 on neointimal hyperplasia development in balloon-injured porcine coronary arteries. Advanced Drug Delivery Reviews. 24:87-108, 1997.

• Shebuski, R.J. and Kilgore, K.S. Role of Inflammatory Mediators in Thrombogenesis. Perspectives in Pharmacology (PIP), J. Pharmacol. Exp. Ther., 300:729-735, 2002.